Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
Childhood Kidney Diseases · 26.12.2023 · 27 (2) · 76-81
DOI: 10.3339/ckd.23.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Childhood Kidney Diseases, online erschienen am 26.12.2023. Verfasst von Hee Sun Beak und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD. Tolvaptan has already been used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.
Zitieren
APA
Beak, H. S., & Cho, M. H. (2023). Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?. Childhood Kidney Diseases, 27(2), 76-81. https://doi.org/10.3339/ckd.23.021
Vancouver
Beak HS, Cho MH. Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?. Childhood Kidney Diseases. 2023;27(2):76-81. doi:10.3339/ckd.23.021
BibTeX
@article{Beak2023,
author = {Beak, Hee Sun and Cho, Min Hyun},
title = {Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?},
journal = {Childhood Kidney Diseases},
year = {2023},
volume = {27},
number = {2},
pages = {76--81},
doi = {10.3339/ckd.23.021}
}
EUVIMED